20Jun2016 Going Public at Beaten Down Valuations? The Crossover Hangover /Luke Timmerman/0/All, Finance, Venture Capital20 Jun 2016 Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.